[go: up one dir, main page]

MX2020009810A - Nuevo uso de las composiciones microbiológicas. - Google Patents

Nuevo uso de las composiciones microbiológicas.

Info

Publication number
MX2020009810A
MX2020009810A MX2020009810A MX2020009810A MX2020009810A MX 2020009810 A MX2020009810 A MX 2020009810A MX 2020009810 A MX2020009810 A MX 2020009810A MX 2020009810 A MX2020009810 A MX 2020009810A MX 2020009810 A MX2020009810 A MX 2020009810A
Authority
MX
Mexico
Prior art keywords
stress
anxiety
exacerbated
psychological
behavioral
Prior art date
Application number
MX2020009810A
Other languages
English (en)
Inventor
Stephen Perrett
Colin Hill
Ted Dinan
Alicja Warda
Original Assignee
Adare Pharmaceuticals Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals Sas filed Critical Adare Pharmaceuticals Sas
Publication of MX2020009810A publication Critical patent/MX2020009810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/137—Delbrueckii
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/143—Fermentum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende células muertas de cepas de Lactobacillus útiles para la protección de sujetos contra el desarrollo de afecciones con componentes conductuales, psicológicos y/o físicos causados o exacerbados por estrés o ansiedad, y/o útiles en el tratamiento de afecciones existentes con componentes conductuales, psicológicos o físicos causados o exacerbados por estrés o ansiedad. Los ejemplos de afecciones específicas incluyen estrés, ansiedad, depresión, trastornos del estado de ánimo, trastornos de sociabilidad, síndrome del intestino irritable, autismo, trastorno del espectro autista, trastorno de estrés postraumático, estrés crónico y una variedad de otras enfermedades relacionadas con el estrés.
MX2020009810A 2018-03-22 2019-03-22 Nuevo uso de las composiciones microbiológicas. MX2020009810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646570P 2018-03-22 2018-03-22
PCT/EP2019/057346 WO2019180263A2 (en) 2018-03-22 2019-03-22 New use of microbiological compositions

Publications (1)

Publication Number Publication Date
MX2020009810A true MX2020009810A (es) 2021-02-18

Family

ID=66092298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009810A MX2020009810A (es) 2018-03-22 2019-03-22 Nuevo uso de las composiciones microbiológicas.

Country Status (8)

Country Link
US (1) US20200405787A1 (es)
EP (1) EP3768287A2 (es)
JP (1) JP2021518439A (es)
KR (1) KR20210003746A (es)
CN (1) CN113453698A (es)
CA (1) CA3094181A1 (es)
MX (1) MX2020009810A (es)
WO (1) WO2019180263A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021204A2 (pt) * 2018-04-18 2021-01-19 Danstar Ferment Ag Composição, método para aliviar ou suprimir os sintomas, método de formulação de uma composição para aliviar ou suprimir os sintomas, uso de uma composição e uso não terapêutico de pelo menos uma cepa bacteriana
EP4142757A1 (en) * 2020-05-01 2023-03-08 Adare Pharmaceuticals SAS Stimulation of the growth of gut bifidobacteria
CN113069469B (zh) * 2021-04-07 2022-12-13 上海市精神卫生中心（上海市心理咨询培训中心） 调节性t细胞在制备治疗孤独症药物或细胞疗法中的应用
WO2022224273A1 (en) * 2021-04-21 2022-10-27 Srikant Dr Niriee Novel psychobiotic compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
WO2004084923A1 (ja) * 2003-03-26 2004-10-07 Takeda Food Products, Ltd. 抗ストレス剤
HUP0700552A2 (en) * 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
JP2013507394A (ja) * 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
WO2012089782A1 (en) * 2010-12-29 2012-07-05 Nestec S.A. Fiber and probiotics for reducing intestinal symptoms related to stress
MX2013007736A (es) * 2010-12-29 2013-07-24 Nestec Sa Una composicion nutricional que comprende fibra y probioticos para reducir sintomas intestinales relacionados con estres.
EP2890808A4 (en) 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
SG11201703193XA (en) * 2014-10-28 2017-05-30 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
KR20170086492A (ko) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
US10363279B2 (en) * 2016-02-20 2019-07-30 Nubiome, Inc. Treatment and prophylaxis for neurological conditions and diseases
CN107308190A (zh) * 2017-07-04 2017-11-03 宇萃达生物科技（苏州）有限公司 调节人体微生态平衡的益生菌组合物及其培养物、制剂、用途

Also Published As

Publication number Publication date
WO2019180263A3 (en) 2019-11-28
CN113453698A (zh) 2021-09-28
WO2019180263A2 (en) 2019-09-26
CA3094181A1 (en) 2019-09-26
EP3768287A2 (en) 2021-01-27
KR20210003746A (ko) 2021-01-12
US20200405787A1 (en) 2020-12-31
JP2021518439A (ja) 2021-08-02

Similar Documents

Publication Publication Date Title
MX2020009810A (es) Nuevo uso de las composiciones microbiológicas.
PH12019502725A1 (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MY172151A (en) Certain chemical entities, compositions and methods
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
EP4353254A3 (en) Methods for treating skin infection by administering an il-4r antagonist
MY162146A (en) Pharmaceutical composition
BR112014002746A8 (pt) filtragem de resultados de pesquisa social
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
AU2016219704A1 (en) Anti-Notch1 antibodies
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MX361392B (es) Composición de fragancia.
WO2015011284A3 (en) Inhibitors of fapp2 and uses thereof
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
IN2014CN02273A (es)
CO6561811A2 (es) Composiciones de etanol
PH12021552521A1 (en) Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof
MX2018001849A (es) Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo.
MD20160112A2 (ro) Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
MX2021015961A (es) Moleculas novedosas.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
WO2018174668A3 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도